Osteosarcoma Clinical Trials
ILC Phase II Clinical Trial for Osteosarcoma
Clinical trials are an important and necessary component of the drug development process, in order to evaluate the safety and efficacy of new drug candidates. Eleison is also developing drug candidate ILC, a lipid-complexed cisplatin administered via inhalation. ILC is currently being evaluated under a Phase II clinical protocol for certain patients with osteosarcoma (bone cancer). If you are interested in learning more about this clinical trial, please visit the US FDA Website
Physicians interested in learning more about or participating in Eleison’s clinical trials are invited to contact Eleison’s Chief Medical Officer, Dr. Forrest Anthony, by telephone at 215-554-3530, or by email at email@example.com
Osteosarcoma (bone cancer) is a rare but debilitating and dangerous disease. About 500 children and young adults are diagnosed with osteosarcoma each year in the United States. Most patients are typically otherwise healthy teenagers when first diagnosed. Standard therapy, a combination of surgery and chemotherapy, is difficult and with serious side effects, but nearly all such patients experience at least an initial remission. Unfortunately, 30-35% of patients will ultimately experience a recurrence of the cancer, usually in the first year or two after diagnosis, but sometimes five or more years later. Although tumor recurrence may occur anywhere in the body, the most common site of recurrence is in the lungs and only in the lungs. The prognosis for relapsed patients with pulmonary tumors is very poor, with five year survival of less than 25%. Eleison’s drug candidate ILC has been designed to delay, prevent, and treat osteosarcoma pulmonary tumors, and is currently being evaluated in a phase II clinical trial.